Bellevue Group AG Sells 39,645 Shares of argenx SE (NASDAQ:ARGX)

Bellevue Group AG lowered its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 593,184 shares of the company's stock after selling 39,645 shares during the period. argenx makes up 7.0% of Bellevue Group AG's holdings, making the stock its largest position. Bellevue Group AG owned approximately 0.98% of argenx worth $364,808,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its holdings in shares of argenx by 138.4% in the fourth quarter. BNP Paribas Financial Markets now owns 10,232 shares of the company's stock valued at $6,293,000 after buying an additional 5,940 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of argenx by 10.0% during the fourth quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after purchasing an additional 639 shares during the period. Acuta Capital Partners LLC lifted its holdings in shares of argenx by 17.1% during the fourth quarter. Acuta Capital Partners LLC now owns 6,910 shares of the company's stock valued at $4,250,000 after purchasing an additional 1,010 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of argenx in the 4th quarter valued at $17,158,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in argenx in the 4th quarter worth about $3,301,000. Institutional investors and hedge funds own 60.32% of the company's stock.

Analyst Ratings Changes

ARGX has been the topic of several analyst reports. Guggenheim lifted their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Wedbush restated an "outperform" rating and issued a $715.00 target price on shares of argenx in a report on Friday, April 11th. Piper Sandler lifted their price target on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a report on Tuesday, January 7th. Finally, HC Wainwright reissued a "buy" rating and set a $720.00 price target on shares of argenx in a research report on Tuesday, April 8th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Price Performance

ARGX traded down $41.54 on Tuesday, hitting $615.11. The company had a trading volume of 476,926 shares, compared to its average volume of 310,514. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The company's fifty day moving average price is $598.80 and its 200 day moving average price is $612.99. The stock has a market cap of $37.56 billion, a price-to-earnings ratio of -698.99 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, sell-side analysts forecast that argenx SE will post 3.13 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.